CAPR Capricor Therapeutics Inc Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:13
Sep 01
Sep 01
Premarket movers show Mag 7 stocks lower, while Capricor, Duolingo.
Premarket movers show Mag 7 stocks lower, while Capricor, Duolingo, and Robinhood gain on analyst upgrades, Fervo jumps on a Google power deal, and GoPro soars 76% after a prior rally.
11:00
Sep 01
Sep 01
Piper Sandler, CFRA, Evercore ISI, Morgan Stanley, BTIG, BMO, UBS, BofA, DA Davidson.
Piper Sandler, CFRA, Evercore ISI, Morgan Stanley, BTIG, BMO, UBS, BofA, DA Davidson, and Jefferies issue multiple upgrades and downgrades with mixed price target adjustments across a broad range of stocks.
15:58
Aug 27
Aug 27
Author added to VERA and BHVN on weakness citing FDA flexibility and narrative shift.
Author added to VERA and BHVN on weakness citing FDA flexibility and narrative shift, while giving secondary looks to REPL, CAPR, and QURE without explicit positions.
LOW
11:58
Aug 25
Aug 25
Raymond James upgrades AMD to Strong Buy with a raised price target.
Raymond James upgrades AMD to Strong Buy with a raised price target, while multiple other analysts issue upgrades and downgrades across various stocks including DT, SMMT, BFH, FLNC, FOUR, MRNA, CAPR, RLI, NTR, KLAR, PAY, DQ, FIVE, and FIS.
13:41
Aug 23
Aug 23
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA.
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA, and discusses past trades without new forward calls on most names.
12:25
Aug 14
Aug 14
Author praises the parent for changing stance on Capricor based on new evidence.
Author praises the parent for changing stance on Capricor based on new evidence, without stating their own position or trade idea.
LOW
11:56
Aug 14
Aug 14
Premarket movers show mixed megacap tech, with notable gains in AeroVironment.
Premarket movers show mixed megacap tech, with notable gains in AeroVironment, Aehr Test Systems, Nubank, Reddit, and Sandisk, while Applied Materials, ARS Pharmaceuticals, Capricor, Gemini Space Station, Globant, and York Space decline on various news.
22:04
Aug 13
Aug 13
The author mocks CAPR longs sarcastically about today's price action without stating a position.
The author mocks CAPR longs sarcastically about today's price action without stating a position or directional call.
LOW
00:37
Aug 12
Aug 12
The author rhetorically dismisses a list of biotechs as failed drugmakers.
The author rhetorically dismisses a list of biotechs as failed drugmakers, but this is sarcastic criticism without a forward-looking short position or trade call.
LOW
17:11
Aug 10
Aug 10
The author defends their binary event call accuracy by listing past winners and losers.
The author defends their binary event call accuracy by listing past winners and losers, but frames it as a track record defense rather than a current position or forward call.
LOW
08:28
Jul 30
Jul 30
KBW upgraded Lemonade to Market Perform, JP Morgan upgraded Sprouts Farmers Market.
KBW upgraded Lemonade to Market Perform, JP Morgan upgraded Sprouts Farmers Market to Overweight with a raised price target, while Piper Sandler downgraded Capricor Therapeutics, PennyMac Financial Services, and Tenable Holdings, and Deutsche Bank downgraded Option Care Health.
11:52
Jul 28
Jul 28
Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight.
Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight, and multiple other analyst upgrades and downgrades are reported across a wide range of stocks with specific price target changes.
16:52
Jul 27
Jul 27
FDA issued a negative regulatory finding on CAPR consistent with author's prior bear thesis.
FDA issued a negative regulatory finding on CAPR consistent with author's prior bear thesis; author previously held a short that resulted in a loss.
MED
13:44
Jul 27
Jul 27
Sell/short CAPR — author argues FDA approval is unlikely because the trial changed its.
Sell/short CAPR — author argues FDA approval is unlikely because the trial changed its pre-specified endpoint and the LVEF result remains barely statistically significant even after that change, suggesting the underlying data is too weak to pass regulatory scrutiny.
MED
12:41
Jul 27
Jul 27
Shkreli warns Capricor about data integrity ahead of a binary readout.
Shkreli warns Capricor about data integrity ahead of a binary readout, but expresses no directional view or position.
LOW
12:36
Jul 27
Jul 27
Pre-market movers include Nvidia discussing a financing backstop for OpenAI's data center.
Pre-market movers include Nvidia discussing a financing backstop for OpenAI's data center, Baker Hughes beating estimates, Rocket Lab winning a Space Force contract, and Fortress Biotech being acquired by Argenx for $77 per share.
12:17
Jul 27
Jul 27
The tweet links to a chart or article about CAPR without providing any explicit position.
The tweet links to a chart or article about CAPR without providing any explicit position or forward-looking call from the author.
LOW
12:07
Jul 27
Jul 27
Short CAPR as Shkreli alleges imminent criminal charges against the CEO and a statistics.
Short CAPR as Shkreli alleges imminent criminal charges against the CEO and a statistics consultant for patient data manipulation — a fraud allegation of this nature risks trial invalidation, FDA scrutiny, and leadership collapse in a small-cap biotech.
HIGH
11:56
Jul 27
Jul 27
Short CAPR; Shkreli explicitly labels the company a complete fraud.
Short CAPR; Shkreli explicitly labels the company a complete fraud, implying terminal structural impairment beyond valuation criticism, though no specific mechanism is stated and no personal short position is disclosed.
MED
00:21
Jul 14
Jul 14
Shkreli dismisses CAPR as a fraudulent retail name in a reply.
Shkreli dismisses CAPR as a fraudulent retail name in a reply, but the statement is an opinion without a forward-looking trade call.
LOW
16:17
Jun 26
Jun 26
Capricor Therapeutics fell 10% after an FDA AdCom was scheduled for July 29.
Capricor Therapeutics fell 10% after an FDA AdCom was scheduled for July 29, with analysts trimming targets and quant indicators rating it a hold, creating near-term uncertainty ahead of the August 22 PDUFA.
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
22:12
May 20
May 20
The author predicts that Capr will eventually face negative consequences.
The author predicts that Capr will eventually face negative consequences, implying a bearish outlook on the stock's future performance.
HIGH
18:31
Mar 10
Mar 10
Shorting the stock based on the speaker's conviction that the company's clinical data is.
Shorting the stock based on the speaker's conviction that the company's clinical data is fraudulent, implying the asset's value is based on false information.
HIGH
20:27
Mar 09
Mar 09
The head of the FDA's division of vaccines and gene therapies set to leave the agency next month... to the expectation maybe a better and some more supportive landscape from the FDA for these kinds of companies. Regulatory bottlenecks are the primary headwind for clinical-stage biotechs. A change in FDA leadership that brings a more lenient or supportive stance will accelerate trial approvals and shorten the timeline to commercialization for biological and gene therapies. LONG. Anticipated deregulation acts as a sector-wide tailwind, disproportionately benefiting small-cap clinical-stage biotechs that rely on smooth FDA pathways. Clinical trials could still fail on efficacy or safety grounds regardless of who is leading the FDA division.
12:07
Feb 24
Feb 24
Highlights strong past biotech performance
Author highlights strong past performance of several asymmetric biotech bets made earlier in the year.
LOW
14:51
Dec 03
Dec 03
Author maintains long asymmetric biotech positions
Author discloses ongoing long positions in three asymmetric biotech bets, highlighting strong recent performance.
MED
12:52
Dec 03
Dec 03
1. THE FACT: The speaker analyzes $CAPR's data, stating "1.2 point improvement on 42 point.
1. THE FACT: The speaker analyzes $CAPR's data, stating "1.2 point improvement on 42 point scale is a 3% improvement vs. placebo -- that can't be stat sig."
2. THE BRIDGE: A 3% improvement is generally considered clinically insignificant, and the speaker's assertion that it "can't be stat sig" (statistically significant) implies the trial results are not robust enough to support efficacy claims. This directly undermines the company's prospects.
3. THE VERDICT: Short CAPR as the reported 3% improvement over placebo is likely not statistically significant, suggesting the drug's efficacy is minimal or non-existent.
About CAPR Analyst Coverage
Buzzberg tracks CAPR (Capricor Therapeutics Inc) across 9 sources. 2 bullish vs 3 bearish calls from 10 analysts. Sentiment: mixed to bearish. 47 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: zerohedge, DeItaone, seedy19tron.